Federal Policy
FDA Proposes Withdrawing Liquid Statin FloLipid Over Missed Reports
The FDA proposed withdrawing approval of FloLipid, a liquid formulation of simvastatin, after manufacturer Salerno Pharmaceuticals failed to file required annual reports, according to a Nov. 18 notice in the Federal Register. These annual reports convey labeling updates and manufacturing and controls information, per FDA policy. The agency is offering Salerno Pharma the chance to request a hearing to argue against the withdrawal. FloLipid was approved in April 2016 and marketed as the first liquid statin available in the U.S. for patients who have trouble swallowing pills; generic simvastatin tablets remain widely available.
Why it mattersMedicaid pharmacy programs and prescribers serving patients who rely on liquid statin formulations may need to transition those patients to generic tablet alternatives if the withdrawal proceeds.